BioWorld - Sunday, December 28, 2025

Articles by Amanda Lanier

Brain and financial charts
Index insights

Design, Sarepta, Wave rise amid overall neurological index decline

July 1, 2024
By Amanda Lanier
In the first five months of 2024, the BioWorld Neurological Diseases Index (BNDI) saw a 10.35% decline, underperforming both the Nasdaq Biotechnology Index (NBI), which rose by 0.7%, and the Dow Jones Industrial Average (DJIA), which increased by 2.64%. This represents an additional drop for BNDI, which closed February with a 4.1% decline. In contrast, in 2023, the BNDI closed with a 4.36% increase, outperforming the NBI, which rose by 3.74%, but not matching the 13.7% rise seen in the DJIA.
Read More
Clinical data illustration
Biopharma clinical updates May 2024

May’s 298 clinical trial updates led by Astrazeneca, Hutchmed and Novartis

June 28, 2024
By Amanda Lanier
In May 2024, BioWorld covered 298 updates across phase I-III clinical trials, surpassing March (261), February (236) and January (252), though falling short of April’s high of 323. Additionally, at the end of May BioWorld revised its reporting criteria for clinical trial updates, focusing mainly on data readouts and excluding trial initiations, enrollment changes and initial patient dosing, thereby impacting the update count relative to prior months.
Read More
FDA Approved stamp with pills, bottle, blister pack
Biopharma regulatory actions and approvals May 2024

Two Eylea biosimilars among 11 FDA drug approvals in May

June 25, 2024
By Amanda Lanier
In May, the U.S. FDA approved 11 new drugs, a significant drop from the 26 approvals in April, which was the sixth-highest monthly total since 2016. This also falls short of March’s record-setting 30 approvals, the highest number recorded by BioWorld.
Read More
FDA Approved stamp with pills, bottle, blister pack
Biopharma regulatory actions and approvals May 2024

Two Eylea biosimilars among 11 FDA drug approvals in May

June 21, 2024
By Amanda Lanier
In May, the U.S. FDA approved 11 new drugs, a significant drop from the 26 approvals in April, which was the sixth-highest monthly total since 2016. This also falls short of March’s record-setting 30 approvals, the highest number recorded by BioWorld.
Read More
Financial line graph

Biopharma index outpaces market benchmarks with an 8% rise

June 21, 2024
By Amanda Lanier
The BioWorld Biopharmaceutical Index (BBI) saw an 8.15% increase at the close of May, outperforming the Dow Jones Industrial Average, which rose by 2.64%, and the Nasdaq Biotechnology Index, which was up by 0.7%. The BBI previously showed a strong performance in Q1, followed by a dip for all three indices in April, before all rebounded in May.
Read More
Biopharma deals May 2024

May biopharma deals hit $18.76B, up 23% from April

June 18, 2024
By Amanda Lanier
Biopharma deal value surged in May to $18.76 billion, up 23% from April's $15.28 billion. This increase follows March’s $8.29 billion and February’s $7.76 billion, although represents a decline from January’s $27.9 billion. The monthly average for 2024 stands at $15.64 billion, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As rose to $4.75 billion in May, an increase from April’s $1.33 billion, which was the lowest figure in nearly a year.
Read More
Handshake with dollar sign and checkmark
Biopharma deals May 2024

May biopharma deals hit $18.76B, up 23% from April

June 14, 2024
By Amanda Lanier
Biopharma deal value surged in May to $18.76 billion, up 23% from April's $15.28 billion. This increase follows March’s $8.29 billion and February’s $7.76 billion, although represents a decline from January’s $27.9 billion. The monthly average for 2024 stands at $15.64 billion, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As rose to $4.75 billion in May, an increase from April’s $1.33 billion, which was the lowest figure in nearly a year.
Read More
Hand pointing at digital M&A screen
Med-tech deals May 2024

J&J acquisition drives May med-tech M&A value to $14.63B

June 14, 2024
By Amanda Lanier
In May, the value of med-tech deals dropped to $85.78 million, marking a 50% decrease from April's $172.37 million but exceeding March's $27 million. The monthly average for deal value in 2024 now stands at $129.7 million, an 84% decline compared to the 2023 monthly average of $886.13 million.
Read More